- Home
- GUG vs CSTL Comparison
GUG vs CSTL Comparison
Compare GUG & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUG
- CSTL
- Stock Information
- Founded
- GUG 2021
- CSTL 2007
- Country
- GUG United States
- CSTL United States
- Employees
- GUG N/A
- CSTL N/A
- Industry
- GUG Trusts Except Educational Religious and Charitable
- CSTL Medical Specialities
- Sector
- GUG Finance
- CSTL Health Care
- Exchange
- GUG Nasdaq
- CSTL Nasdaq
- Market Cap
- GUG 470.0M
- CSTL 456.2M
- IPO Year
- GUG N/A
- CSTL 2019
- Fundamental
- Price
- GUG $15.09
- CSTL $15.95
- Analyst Decision
- GUG
- CSTL Strong Buy
- Analyst Count
- GUG 0
- CSTL 6
- Target Price
- GUG N/A
- CSTL $37.67
- AVG Volume (30 Days)
- GUG 108.9K
- CSTL 527.3K
- Earning Date
- GUG 01-01-0001
- CSTL 05-05-2025
- Dividend Yield
- GUG 9.67%
- CSTL N/A
- EPS Growth
- GUG N/A
- CSTL N/A
- EPS
- GUG N/A
- CSTL N/A
- Revenue
- GUG N/A
- CSTL $347,083,000.00
- Revenue This Year
- GUG N/A
- CSTL N/A
- Revenue Next Year
- GUG N/A
- CSTL $1.80
- P/E Ratio
- GUG N/A
- CSTL N/A
- Revenue Growth
- GUG N/A
- CSTL 38.43
- 52 Week Low
- GUG $12.71
- CSTL $15.45
- 52 Week High
- GUG $15.06
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- GUG 49.69
- CSTL 33.63
- Support Level
- GUG $14.97
- CSTL $15.45
- Resistance Level
- GUG $15.35
- CSTL $16.43
- Average True Range (ATR)
- GUG 0.24
- CSTL 0.59
- MACD
- GUG -0.03
- CSTL 0.04
- Stochastic Oscillator
- GUG 15.38
- CSTL 15.93
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.